Why Amgen (AMGN) Is a Top Cheap NASDAQ Stock to Buy After CFO Retirement

Amgen (AMGN) is a cheap NASDAQ stock to buy after CFO Peter Griffith's May 19 retirement. Learn what investors should watch and why AMGN stays attractive.

Amgen (AMGN) just became an even more talked-about name among cheap NASDAQ stocks to buy after the company announced the retirement of Executive Vice President and Chief Financial Officer Peter Griffith on May 19. Griffith, who served as CFO since 2020, played a key role in strengthening Amgen’s financial position and shaping capital allocation strategy — news that has investors parsing the implications for the biotech giant.

Leadership transitions can trigger short-term volatility, but they also shine a spotlight on fundamentals. For value-seeking investors scanning NASDAQ stocks, Amgen’s broad product portfolio, steady cash generation, and history of shareholder-friendly policies make it worth consideration. The CFO’s tenure supported disciplined capital allocation, and the company’s underlying business — built on established therapies and ongoing R&D — remains intact.

What to watch next: first, the succession plan. Markets prefer clarity, so investors should follow company statements about an interim or permanent replacement and any updates to guidance. Second, look for commentary on capital allocation: will the new financial leadership maintain the same mix of dividends, buybacks, and reinvestment in the pipeline? Third, monitor upcoming earnings and analyst revisions, which will reveal how management frames near-term priorities.

Why investors call AMGN a cheap NASDAQ stock to buy: the name often trades at a valuation that appeals to income and value investors while offering exposure to biotech innovation. Amgen’s ability to convert research into revenue gives it a defensive edge versus smaller biotech plays. For those focused on income, Amgen’s dividend policy and history of returning cash to shareholders are attractive components of the investment case.

Risks remain: regulatory setbacks, competitive pressures, or slower-than-expected launches can affect performance. But for investors prioritizing established biotech names among NASDAQ stocks to buy, Amgen’s combination of financial discipline, pipeline depth, and shareholder-focused capital allocation helps explain why it’s on many watchlists.

Bottom line: the CFO retirement is a meaningful corporate event, but it doesn’t erase Amgen’s core strengths. Monitor succession updates, earnings commentary, and capital-allocation signals to decide if AMGN fits your portfolio as one of the cheaper NASDAQ opportunities with biotech upside.

Back